Faculty Bibliography

After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the only drug available for the treatment of GH deficiency. In 1985, recombinant GH became available, and the modalities of GH therapies changed dramatically as the supply was unlimited. New indications for GH in pediatrics and adult medicine were developed. Treatment was daily. Now in 2021 long-acting GH (LAGH) became available the world over making GH therapy more patient-friendly and even showing slightly greater efficacy than daily GH therapy. We are now entering a new era of LAGH therapy for pediatric and adult use with new formulations of GH, which will predictably be the preferred form of GH therapy for years to come increasing adherence to GH therapy and possibly even efficacy, that is, better growth rate. The continued availability of new safety data will further solidify the use of LAGH in clinical medicine.

Turner syndrome is the most common sex chromosome abnormality in women. Infertility and short stature are the most striking findings seen in these patients. Unfortunately, many girls are still being diagnosed too late and therefore early diagnosis and treatment key. Turner syndrome affects many systems of the body; therefore, a comprehensive approach is key for therapeutic intervention.

PURPOSE/OBJECTIVE:The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess the long-term safety and efficacy of weekly administered long-acting growth hormone (LAGH) lonapegsomatropin in children with growth hormone deficiency (GHD). METHODS:Eligible subjects completing a prior Phase 3 lonapegsomatropin parent trial (heiGHt or fliGHt) were invited to participate. All subjects were treated with lonapegsomatropin. Subjects in the US switched to the TransCon hGH Auto-Injector when available.​ Endpoints were long-term safety, annualized height velocity (AHV), pharmacodynamics (insulin-like growth factor-1 standard deviation score [IGF-1 SDS] values), and patient- and caregiver-reported assessments of convenience and tolerability. RESULTS:Lonapegsomatropin treatment during enliGHten was associated with continued improvements in height SDS through Week 104 in treatment-naïve subjects from the heiGHt trial (-2.89 to -1.37 for- the lonapegsomatropin group; -3.0 to -1.52 for the daily somatropin group). Height SDS also continued to improve among switch subjects from the fliGHt trial (-1.42 at fliGHt baseline to -0.69 at Week 78). After 104 weeks, the average bone age/chronological age ratio for each treatment group was 0.8 (0.1), showing only minimal advancement of bone age relative to chronological age with continued lonapegsomatropin treatment among heiGHt subjects. Fewer local tolerability reactions were reported with the TransCon hGH Auto-Injector compared with syringe/needle. CONCLUSIONS:Treatment with lonapegsomatropin continued to be safe and well-tolerated, with no new safety signals identified. Children treated with once-weekly lonapegsomatropin showed continued improvement of height SDS through the 2nd year of therapy without excess advancement of bone age.

CONTEXT/BACKGROUND:Current GH therapy requires daily injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for treatment of GH deficiency (GHD). OBJECTIVE:Evaluate the efficacy, safety, and tolerability of once-weekly somapacitan after 3 years of treatment. DESIGN/METHODS:A multicenter, randomized, controlled, phase 2 study comparing somapacitan and once-daily GH for 156 weeks (NCT02616562). SETTING/METHODS:Twenty-nine sites in 11 countries. PATIENTS/METHODS:Fifty-nine children with GHD randomized (1:1:1:1) and exposed to treatment. Fifty-three children completed the 3-year period. INTERVENTIONS/METHODS:Patients received somapacitan (0.04 [n=14], 0.08 [n=15] or 0.16 [n=14] mg/kg/week) or daily GH (n=14) (0.034 mg/kg/day, equivalent to 0.238 mg/kg/week) subcutaneously during the first year, after which all patients on somapacitan received 0.16 mg/kg/week. MAIN OUTCOME MEASURES/METHODS:Height velocity (HV) at year 3; changes from baseline in height standard deviation score (HSDS), HVSDS and IGF-I SDS. RESULTS:The estimated treatment difference (95% CI) in HV for somapacitan 0.16/0.16 mg/kg/week versus daily GH at year 3 was 0.8 cm/year (-0.4; 2.1). Change in HVSDS from baseline to year 3 was comparable between somapacitan 0.16/0.16 mg/kg/week, the pooled somapacitan groups, and daily GH. A gradual increase in HSDS from baseline was observed for all groups. At year 3, mean HSDS was similar for the pooled somapacitan groups and daily GH. Change from baseline to year 3 in mean IGF-I SDS was similar across treatments. CONCLUSIONS:Once-weekly somapacitan in children with GHD showed sustained efficacy over 3 years in all assessed height-based outcomes with similar safety and tolerability to daily GH.

INTRODUCTION/BACKGROUND:The phase 3 fliGHt Trial evaluated the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy to lonapegsomatropin. METHODS:This multicenter, open-label, 26-week phase 3 trial took place at 28 sites across 4 countries (Australia, Canada, New Zealand, and the USA). The trial enrolled 146 children with GHD, 143 of which were previously treated with daily somatropin. All subjects received once-weekly lonapegsomatropin 0.24 mg human growth hormone/kg/week. The primary outcome measure was safety and tolerability of lonapegsomatropin over 26 weeks. Secondary outcome measures assessed annualized height velocity (AHV), height standard deviation score (SDS), and IGF-1 SDS at 26 weeks. RESULTS:Subjects had a mean prior daily somatropin dose of 0.29 mg/kg/week. Treatment-emergent adverse events (AEs) reported were similar to the published AE profile of daily somatropin therapies. After switching to lonapegsomatropin, the least-squares mean (LSM) AHV was 8.7 cm/year (95% CI: 8.2, 9.2) at Week 26 and LSM height SDS changed from baseline to Week 26 of +0.25 (95% CI: 0.21, 0.29). Among switch subjects, the LSM for average IGF-1 SDS was sustained at Weeks 13 and 26, representing an approximate 0.7 increase from baseline (prior to switching from daily somatropin therapy). Patient-reported outcomes indicated a preference for weekly lonapegsomatropin among both children and their parents. CONCLUSIONS:Lonapegsomatropin treatment outcomes were as expected across a range of ages and treatment experiences. Switching to lonapegsomatropin resulted in a similar AE profile to daily somatropin therapy.

Objectives Lonapegsomatropin (TransCon hGH) is an investigational once-weekly prodrug of somatropin for the treatment of GHD. Lonapegsomatropin demonstrated efficacy and safety in treatment-naive and -experienced children in the 52-week heiGHt Trial and 26-week fliGHt Trial, respectively. Results are reported for heiGHt and fliGHt subjects who continued into the ongoing open-label, long-term extension enliGHten Trial. Methods At a starting dose of 0.24 mg hGH/kg/wk, treatment-naive subjects received lonapegsomatropin (Group A; vial/syringe) or daily somatropin (Group B; pen device) in heiGHt, or switched to lonapegsomatropin from daily somatropin in fliGHt (Group C; vial/syringe). Upon entry into enliGHten, all subjects received lonapegsomatropin (vial/syringe), with switch to TransCon hGH Auto-Injector when available. Results A total of 298 subjects continued into enliGHten (A:n=103; B:n=55; C:n=140). The mean dose remained approximately 0.24 mg hGH/kg/wk for Group A/B at Week 104 and was 0.20 mg hGH/kg/wk for Group C at Week 78. The treatment difference in least-squares mean DELTA height SDS (HSDS) (A vs B) at the end of heiGHt (Week 52, 1.10 vs 0.96, P=0.015) continued to trend through Week 104 (1.61 vs 1.49, P=0.158). For Groups A/B, annualized height velocity (AHV) was in the expected range for 2nd year therapy; among children who switched (B), a lower-than-expected attenuation in 2nd year AHV suggested an improved treatment effect of lonapegsomatropin relative to the previous daily somatropin. For Group C, HSDS improved from -1.42 at trial baseline to -0.69 at Week 78. Mean (SD) average IGF-1 SDS remained stable and generally within the expected range for all groups (Week 104, A:0.95 [1.22], B:1.04 [1.25]; Week 78, C:1.81 [1.08]). Across all phase 3 trials, lonapegsomatropin produced a dose linear IGF-1 response, with a dose reduction of 0.02 mg hGH/kg/wk on average resulting in a reduction in IGF-1 SDS of 0.16, consistent with what was observed in the dose-ranging phase 2 trial. With continued lonapegsomatropin treatment, the AE profile remained consistent with what was observed in the parent trials, with no new safety signals. As of the data cut, a total of 5 subjects have met or exceeded their target height and 11 subjects have grown to within 2 cm below their target height. Conclusions Children treated with lonapegsomatropin showed continued improvement of HSDS through their 2nd year of therapy while demonstrating a safety profile generally comparable to that of daily somatropin therapy

Objectives We are investigating for the first time the reliability of using a highly sensitive GH-ELISA assay for quantification of growth hormone levels from dried blood spots (

Lonapegsomatropin (TransCon hGH) is an investigational once-weekly prodrug of somatropin for the treatment of GHD. Previous trials in treatment-naive (52-week heiGHt Trial) and treatment-experienced children (26-week fliGHt Trial) have reported the efficacy and safety of lonapegsomatropin. Subjects were eligible to enter the open-label extension enliGHten Trial, which continues to evaluate weekly lonapegsomatropin in pediatric GHD. In heiGHt, treatment-naive subjects received lonapegsomatropin (Group A; vial/syringe) or daily somatropin (Group B; pen device). In fliGHt, treatment-experienced subjects switched to lonapegsomatropin from daily somatropin (Group C; vial/syringe). Lonapegsomatropin was administered at a starting dose of 0.24 mg hGH/kg/wk. Upon entry into enliGHten, all subjects received lonapegsomatropin (vial/ syringe), and switched to TransCon hGH Auto-Injector pending regional availability. A total of 298 (of 303 eligible) subjects continued into enliGHten (A: n=103; B: n=55; C: n=140). The mean dose remained approximately 0.24 mg hGH/kg/wk for Group A/B at Week 104 and was 0.20 mg hGH/kg/wk for Group C at Week 78. Subjects starting heiGHt on daily somatropin who switched to lonapegsomatropin continued to approach their average parental height, with height standard deviation score (SDS) improving from -3.0 at baseline to -1.52 at Week 104. Subjects from the fliGHt Trial also continued to approach their average parental height, with height SDS improving from -1.42 at fliGHt baseline to -0.69 at Week 78. Observed Mean annualized height velocity (AHV) at Week 78 was 8.4 cm/year. heiGHt subjects starting lonapegsomatropin continued to approach their average parental height, with height SDS improving from -2.89 at baseline to -1.37 at Week 104. As of the data cut (01 June 2020), 5 subjects have met or exceeded their target height and 11 subjects have grown to within 2 cm of their target height. Mean (SD) average IGF-1 SDS remained stable and generally within the expected range for all groups (Week 104, A:0.95 [1.22], B:1.04 [1.25]; Week 78, C:1.81 [1.08]). Across all phase 3 trials, lonapegsomatropin produced a dose linear IGF-1 response. With lonapegsomatropin treatment, the adverse event (AE) profile remained consistent with what was observed in the parent trials, with no new safety signals, comparable tolerability, and a mean body mass index (BMI) SDS approaching zero. Across the broad population of the phase 3 program, subjects treated with lonapegsomatropin for up to 2 years continued to approach their average parental height, with a safety profile comparable to daily somatropin, including a similar AE profile, tolerability, and stable BMI

Growth hormone (GH) replacement therapy currently requires daily subcutaneous injections. Somapacitan is a long-acting GH-derivative in development for once-weekly use in children with GH deficiency (GHD). A phase 2, multinational, randomised, open-label, controlled trial (NCT02616562) investigated the efficacy and safety of somapacitan compared with daily GH (NorditropinR). GH-treatment-naive prepubertal children with GHD received 0.04 (n=16), 0.08 (n=15) or 0.16 mg/kg/week (n=14) somapacitan, or daily GH 0.034 mg/kg/day (0.24 mg/kg/week; n=14) for 1 year, followed by a 2-year safety extension with all patients on somapacitan (n=45) receiving 0.16 mg/kg/week, while daily GH dose was unaltered. Safety endpoints comprised frequency of adverse events (AEs). The 1-year and 2-year results have been reported previously. Here, we report the efficacy and safety of somapacitan after 3 years of treatment. At year 3, mean (SD) height velocity (HV) was 8.9 (1.7), 7.8 (1.5) and 8.4 (1.7) cm/year for 0.04/0.16 mg/kg/week, 0.08/0.16 mg/kg/ week and 0.16/0.16 mg/kg/week somapacitan, respectively, vs 7.6 (2.0) cm/year for daily GH. Change in mean (SD) height standard deviation score (SDS) from baseline to 3 years was 2.39 (1.00), 2.37 (0.97) and 2.67 (1.42) for somapacitan, respectively, vs 2.10 (0.85) for daily GH. The observed HV results for the somapacitan groups and daily GH arm in the third year, were similar. Change in insulin-like growth factor-I SDS from baseline to year 3 was 3.26 (1.04), 3.52 (1.43) and 3.66 (1.29) for somapacitan, respectively, vs 3.40 (1.58) for daily GH. Number of AEs (% of patients) was as follows: somapacitan 0.04/0.16 mg/kg/week, 72 (75.0%); 0.08/0.16 mg/kg/week, 126 (93.3%); 0.16/0.16 mg/kg/week, 120 (100%); and daily GH, 95 (100%). In all treatment groups, the rate of AEs per 100 patientyears of exposure was lower in the 2-year safety extension than the first year. The most common AEs across the pooled somapacitan groups were pyrexia (40% for somapacitan and 14% for daily GH), influenza (20% and 21%), nasopharyngitis (16% and 21%), vomiting (13% and 7%), constipation (11% and 0%), allergic rhinitis (11% and 21%), otitis media (11% and 7%), tonsillitis (11% and 0%) and gastroenteritis (11% and 14%). Most AEs were mild to moderate and unlikely to be treatment related. These 3-year data support the efficacy results observed in the first and second year of somapacitan treatment of GHD; no new safety signals were observed